Research Progress of Mucin in Tumor Immunotherapy

doi:10.19586/j.2095-2341.2023.0017

Current Biotechnology ›› 2023, Vol. 13 ›› Issue (3): 390-398.DOI: 10.19586/j.2095-2341.2023.0017

• Reviews • Previous Articles Next Articles

Research Progress of Mucin in Tumor Immunotherapy

Lang GAO(), Sixue YU, Chunsen YUAN, Zhiwei SHAN, Pengxiang ZHAO()

Faculty of Environment and Life，Beijing University of Technology，Beijing 100124，China

Received:2023-02-17 Accepted:2023-03-21 Online:2023-05-25 Published:2023-06-12
Contact: Pengxiang ZHAO

黏蛋白在肿瘤免疫治疗中的研究进展

高朗(), 于思雪, 袁春森, 单志伟, 赵鹏翔()

北京工业大学环境与生命学部，北京 100124

通讯作者: 赵鹏翔
作者简介:高朗 E-mail: 15611140435@163.com；
基金资助:
北京市科技新星计划交叉合作课题项目(20220484218)

Abstract

Abstract:

The mucin （MUC） family is a group of highly glycosylated macromolecules，which is mainly distributed in the body of various lumen surface， playing a role in protecting and lubricating epithelial cells. Many studies have shown that mucins play an important role in the occurrence and development of tumors. Therefore， some mucins have been identified as tumor markers and become promising tumor therapeutic targets. This paper reviewed the current mucin-targeted tumor therapy， including small molecule inhibitors， antibody therapy， vaccines， etc， hoping to provide theoretical reference for the development and optimization of clinical tumor diagnosis and treatment methods.

Key words: mucin, tumour, immunotherapy, vaccine

摘要：

黏蛋白是一类主要由黏多糖组成的高分子量糖蛋白，其主要分布在人体的各种管腔内表面，对上皮细胞起到保护和润滑作用。多项研究表明，黏蛋白在肿瘤的发生发展中扮演着重要角色，因此，部分黏蛋白被确定为肿瘤标志物，成为很有前景的肿瘤治疗靶点。综述了目前以黏蛋白为靶点的肿瘤治疗方案，包括小分子抑制剂、抗体疗法、疫苗等方面，以期为临床肿瘤诊治方法的发展与优化提供理论参考。

关键词: 黏蛋白, 肿瘤, 免疫疗法, 疫苗

CLC Number:

R730.51

Lang GAO, Sixue YU, Chunsen YUAN, Zhiwei SHAN, Pengxiang ZHAO. Research Progress of Mucin in Tumor Immunotherapy[J]. Current Biotechnology, 2023, 13(3): 390-398.

高朗, 于思雪, 袁春森, 单志伟, 赵鹏翔. 黏蛋白在肿瘤免疫治疗中的研究进展[J]. 生物技术进展, 2023, 13(3): 390-398.

Figures/Tables 4

References 66

1	LEE D, CHOI S, PARK Y, et al.. Mucin1 and Mucin16: therapeutic targets for cancer therapy[J/OL]. Pharmaceuticals, 2021, 14(10): 1053[2023-02-16]. .
2	LI W, HAN Y, SUN C, et al.. Novel insights into the roles and therapeutic implications of MUC1 oncoprotein via regulating proteins and non-coding RNAs in cancer[J]. Theranostics, 2022, 12(3): 999-1011.
3	RACHAGANI S, TORRES M P, MONIAUX N, et al.. Current status of mucins in the diagnosis and therapy of cancer[J]. Biofactors, 2009, 35(6): 509-527.
4	SHENG Y H, HASNAIN S Z. Mucus and mucins: the underappreciated host defence system[J/OL]. Front. Cell. Infect. Microbiol., 2022, 12: 856962[2023-02-16]. .
5	LI Z, YANG D, GUO T, et al.. Advances in MUC1-mediated breast cancer immunotherapy[J/OL]. Biomolecules, 2022, 12(7): 952[2023-02-16]. .
6	MA Q, SONG J, WANG S, et al.. MUC1 regulates AKT signaling pathway by upregulating EGFR expression in ovarian cancer cells[J/OL]. Pathol. Res. Pract., 2021, 224: 153509[2023-02-16]. .
7	XIA C, DONG X, LI H, et al.. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin. Med. J., 2022, 135(5): 584-590.
8	KUFE D W. MUC1-C in chronic inflammation and carcinogenesis; emergence as a target for cancer treatment[J]. Carcinogenesis, 2020, 41(9): 1173-1183.
9	RAINA D, AHMAD R, JOSHI M D, et al.. Direct targeting of the Mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells[J]. Cancer Res., 2009, 69(12): 5133-5141.
10	SHIBA S, MIKI A, OHZAWA H, et al.. Functional expression of Mucin1 in human duodenal adenocarcinoma[J]. J. Surg. Res., 2019, 238: 79-89.
11	ZHAO Y, WU T, WANG L, et al.. Targeting MUC1-C reverses the cisplatin resistance of esophageal squamous cell carcinoma in vitro and in vivo[J]. Transl. Cancer Res., 2021, 10(2): 645-655.
12	SHIGETA K, HASEGAWA M, KIKUCHI E, et al.. Role of the MUC1-C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma[J]. Cancer Sci., 2020, 111(10): 3639-3652.
13	WU H, XIAO Z, WANG K, et al.. MiR-145 is downregulated in human ovarian cancer and modulates cell growth and invasion by targeting p70S6K1 and MUC1[J]. Biochem. Biophys. Res. Commun., 2013, 441(4): 693-700.
14	WANG X, ZHOU X, ZENG F, et al.. miR-485-5p inhibits the progression of breast cancer cells by negatively regulating MUC1[J]. Breast Cancer, 2020, 27(4): 765-775.
15	SRIVASTAVA S K, BHARDWAJ A, SINGH S, et al.. MicroRNA-150 directly targets MUC4 and suppresses growth and malignant behavior of pancreatic cancer cells[J]. Carcinogenesis, 2011, 32(12): 1832-1839.
16	GONGSUN X, ZHAO Y, JIANG B, et al.. Inhibition of MUC1-C regulates metabolism by AKT pathway in esophageal squamous cell carcinoma[J]. J. Cell. Physiol., 2019, 234(7): 12019-12028.
17	TAGDE A, RAJABI H, STROOPINSKY D, et al.. MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia[J]. Oncotarget, 2016, 7(26): 38974-38987.
18	STROOPINSKY D, RAJABI H, NAHAS M, et al.. MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanism[J]. J. Cell. Mol. Med., 2018, 22(8): 3887-3898.
19	YE Z, SHEN N, WENG Y, et al.. Low miR-145 silenced by DNA methylation promotes NSCLC cell proliferation,migration and invasion by targeting mucin 1[J]. Cancer Biol. Ther., 2015, 16(7): 1071-1079.
20	TRÉHOUX S, LAHDAOUI F, DELPU Y, et al.. Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells[J]. BBA Mol. Cell Res., 2015, 1853(10): 2392-2403.
21	LI X, ZHOU L, LUO H, et al.. The long noncoding RNA MIR210HG promotes tumor metastasis by acting as a ceRNA of miR-1226-3p to regulate mucin-1c expression in invasive breast cancer[J]. Aging, 2019, 11(15): 5646-5665.
22	RADHAKRISHNAN P, MOHR A M, GRANDGENETT P M, et al.. MicroRNA-200c modulates the expression of MUC4 and MUC16 by directly targeting their coding sequences in human pancreatic cancer[J/OL]. PLoS ONE, 2013, 8(10): e73356[2023-02-16]. .
23	BOSE M, SANDERS A, DE C, et al.. Targeting tumor-associated MUC1 overcomes anoikis-resistance in pancreatic cancer[J]. Transl. Res., 2023, 253: 41-56.
24	DANIELCZYK A, STAHN R, FAULSTICH D, et al.. PankoMab: a potent new generation anti-tumour MUC1 antibody[J]. Cancer Immunol. Immun., 2006, 55(11): 1337-1347.
25	FIEDLER W, DEDOSSO S, CRESTA S, et al.. A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas[J]. Eur. J. Cancer, 2016, 63: 55-63.
26	BREWER M, ANGIOLI R, SCAMBIA G, et al.. Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: a randomized phase Ⅱ study[J]. Gynecol. Oncol., 2020, 156(3): 523-529.
27	BATTAGLIA A, BUZZONETTI A, FOSSATI M, et al.. Correction to: translational immune correlates of indirect antibody immunization in a randomized phase Ⅱ study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients[J/OL]. Cancer Immunol. Immu., 2020, 69(7): 1389[2023-02-16]. .
28	NICOLAZZI C, CARON A, TELLIER A, et al.. An antibody-drug conjugate targeting MUC1-associated carbohydrate CA6 shows promising antitumor activities[J]. Mol. Cancer Ther., 2020, 19(8): 1660-1669.
29	LEE E K, LIU J F. Antibody-drug conjugates in gynecologic malignancies[J]. Gynecol. Oncol., 2019, 153(3): 694-702.
30	LIU J F, MOORE K N, BIRRER M J, et al.. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer[J]. Ann. Oncol., 2016, 27(11): 2124-2130.
31	BAYBUTT T R, FLICKINGER J C, CAPAROSA E M, et al.. Advances in chimeric antigen receptor T-cell therapies for solid tumors[J]. Clin. Pharmacol. Ther., 2019, 105(1): 71-78.
32	LEDERMANN J A, ZURAWSKI B, RASPAGLIESI F, et al.. Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase Ⅱ study[J/OL]. ESMO Open, 2022, 7(1): 100311[2023-02-16]. .
33	PAN D, TANG Y, TONG J, et al.. An antibody-drug conjugate targeting a GSTA glycosite-signature epitope of MUC1 expressed by non-small cell lung cancer[J]. Cancer Med., 2020, 9(24): 9529-9540.
34	PANCHAMOORTHY G, JIN C, RAINA D, et al.. Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate[J/OL]. JCI Insight, 2018, 3(12): 99880[2023-02-16]. .
35	ZHOU R, YAZDANIFAR M, ROY L D, et al.. CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth[J/OL]. Front. Immunol., 2019, 10: 01149[2023-02-16]. .
36	MEI Z, ZHANG K, LAM A K Y, et al.. MUC1 as a target for CAR-T therapy in head and neck squamous cell carinoma[J]. Cancer Med., 2020, 9(2): 640-652.
37	GONG Y F, ZHOU Q B, LIAO Y D, et al.. Optimized construction of MUC1-VNTR(n) DNA vaccine and its anti-pancreatic cancer efficacy[J]. Oncol. Lett., 2017, 13(4): 2198-2206.
38	SON H, JEONG H, APOSTOLOPOULOS V, et al.. MUC1 expressing tumor growth was retarded after human mucin 1 (MUC1) plasmid DNA immunization[J/OL]. Int. J. Immunopathol. Pharmacol., 2022, 36:1042695475[2023-02-16]. .
39	GAO T, CEN Q, LEI H. A review on development of MUC1-based cancer vaccine[J/OL]. Biomed. Pharmacother., 2020, 132: 110888[2023-02-16]. .
40	ARRIOLA E, OTTENSMEIER C. TG4010: a vaccine with a therapeutic role in cancer[J]. Immunotherapy, 2016, 8(5): 511-519.
41	QUOIX E, LENA H, LOSONCZY G, et al.. TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial[J]. Lancet Oncol. 2016, 17(2): 212-223.
42	GATTI-MAYS M E, REDMAN J M, DONAHUE R N, et al.. A phase I trial using a multitargeted recombinant adenovirus 5 (CEA/MUC1/Brachyury)-based immunotherapy vaccine regimen in patients with advanced cancer[J]. Oncologist, 2020, 25(6): 479-899.
43	GRAY H J, BENIGNO B, BEREK J, et al.. Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial[J/OL]. J. Immunother. Cancer, 2016, 4(1): 0137x[2023-02-16]. .
44	PAN J, ZENG W, JIA J, et al.. A novel therapeutic tumor vaccine targeting MUC1 in combination with PD-L1 elicits specific anti-tumor immunity in mice[J/OL]. Vaccines, 2022, 10(7): 1092[2023-02-16]. .
45	SHINDO Y, HAZAMA S, MAEDA Y, et al.. Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer[J/OL]. J. Transl. Med., 2014, 12(1): 175[2023-02-16]. .
46	CHEN J, GUO X, LI H, et al.. Generation of CTL responses against pancreatic cancer in vitro using dendritic cells co-transfected with MUC4 and survivin RNA[J]. Vaccine, 2013, 31(41): 4585-4590.
47	CARMON L, AVIVI I, KOVJAZIN R, et al.. Phase Ⅰ/Ⅱ study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients[J]. Br. J. Haematol., 2015, 169(1): 44-56.
48	WONG J C, LAO C T, YOUSIF M M, et al.. Fast tracking-vaccine safety, efficacy, and lessons learned: a narrative review[J/OL]. Vaccines, 2022, 10(8): 1256[2023-02-16]. .
49	BROCKHAUSEN I, MELAMED J. Mucins as anti-cancer targets: perspectives of the glycobiologist[J]. Glycoconjugate J., 2021, 38(4): 459-474.
50	CAI H, CHEN M, SUN Z, et al.. Self-adjuvanting synthetic antitumor vaccines from MUC1 glycopeptides conjugated to T-cell epitopes from tetanus toxoid[J]. Angew. Chem. Int. Edit., 2013, 52(23): 6106-6110.
51	BRINÃS R P, SUNDGREN A, SAHOO P, et al.. Design and synthesis of multifunctional gold nanoparticles bearing tumor-associated glycopeptide antigens as potential cancer vaccines[J]. Bioconjugate Chem., 2012, 23(8): 1513-1523.
52	LIU C, XIE Y, SUN B, et al.. MUC1- and survivin-based DNA vaccine combining immunoadjuvants CpG and interleukin-2 in a bicistronic expression plasmid generates specific immune responses and antitumour effects in a murine colorectal carcinoma model[J]. Scand. J. Immunol., 2018, 87(2): 63-72.
53	ARRIOLA E, OTTENSMEIER C. TG4010: a vaccine with a therapeutic role in cancer[J]. Immunotherapy, 2016, 8(5): 511-519.
54	BILUSIC M, MCMAHON S, MADAN R A, et al.. Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)[J/OL]. J. Immunother. Cancer, 2021, 9(3): e2374 [2023-02-16]. .
55	SINGER C F, PFEILER G, HUBALEK M, et al.. Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: results from a prospective, randomised, neoadjuvant phase Ⅱ study (ABCSG 34)[J]. Eur. J. Cancer, 2020, 132: 43-52.
56	BUTTS C D, SOCINSKI M A P, MITCHELL P L M, et al.. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage Ⅲ non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial[J]. Lancet Oncol., 2014, 15(1): 59-68.
57	XIA W, WANG J, XU Y, et al.. L-BLP25 as a peptide vaccine therapy in non-small cell lung cancer: a review[J]. J. Thorac. Dis., 2014, 6(10): 1513-1520.
58	ROSSMANN E, OSTERBORG A, LOFVENBERG E, et al.. Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study[J]. Hum.Vacc. Immunother., 2014, 10(11): 3394-3408.
59	MOEHLER M, FOLPRECHT G, HEINEMANN V, et al.. Survival after secondary liver resection in metastatic colorectal cancer: comparing data of three prospective randomized European trials (LICC,CELIM,FIRE-3)[J]. Int. J. Cancer, 2022, 150(8): 1341-1349.
60	SCHIMANSKI C C, KASPER S, HEGEWISCH-BECKER S, et al.. Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase Ⅱ trial (LICC)[J/OL]. Onco. Immunol., 2020, 9(1): 1806680[2023-02-16]. .
61	KIMURA T, MCKOLANIS J R, DZUBINSKI L A, et al.. MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study[J]. Cancer Prev. Res., 2013, 6(1): 18-26.
62	MILES D, ROCHÉ H, MARTIN M, et al.. Phase Ⅲ multicenter clinical trial of the Sialyl-Tn (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer[J]. Oncologist, 2011, 16(8): 1092-1100.
63	IBRAHIM N K, MURRAY J L, ZHOU D, et al.. Survival advantage in patients with metastatic breast cancer receiving endocrine therapy plus Sialyl Tn-KLH vaccine: post hoc analysis of a large randomized trial[J]. J. Cancer, 2013, 4(7): 577-584.
64	BARROS L, COUTO S, DA S S D, et al.. Systematic review of available CAR-T cell trials around the world[J/OL]. Cancers, 2022, 14(11): 2667‍[2023-02-16]. .
65	GAUTAM S K, KUMAR S, CANNON A, et al.. MUC4 mucin-a therapeutic target for pancreatic ductal adenocarcinoma[J]. Expert Opin. Ther. Tar., 2017, 21(7): 657-669.
66	STERGIOU N, URSCHBACH M, GABBA A, et al.. The development of vaccines from synthetic tumor-associated mucin glycopeptides and their glycosylation-dependent immune response[J]. Chem. Rec., 2021, 21(11): 3313-3331.

抑制剂种类	药物名称	肿瘤类型	研究现状	参考文献
多肽	GO-203	人十二指肠腺癌	临床前研究	[10]
		食管鳞状细胞癌	临床前研究	[11, 16]
		尿路上皮癌	临床前研究	[12]
		急性髓系白血病	临床前研究	[17-18]
miRNA	miR-145	非小细胞肺癌	临床前研究	[19]
	miR-145	卵巢癌	临床前研究	[13]
	miR-29a，miR-330-5p	胰腺癌	临床前研究	[20]
	miR-1226-3p	侵袭性乳腺癌症	临床前研究	[21]
	miR-150	胰腺癌	临床前研究	[15]
	miR-200c	胰腺癌	临床前研究	[22]

抑制剂种类	药物名称	肿瘤类型	研究现状	参考文献
多肽	GO-203	人十二指肠腺癌	临床前研究	[10]
		食管鳞状细胞癌	临床前研究	[11, 16]
		尿路上皮癌	临床前研究	[12]
		急性髓系白血病	临床前研究	[17-18]
miRNA	miR-145	非小细胞肺癌	临床前研究	[19]
	miR-145	卵巢癌	临床前研究	[13]
	miR-29a，miR-330-5p	胰腺癌	临床前研究	[20]
	miR-1226-3p	侵袭性乳腺癌症	临床前研究	[21]
	miR-150	胰腺癌	临床前研究	[15]
	miR-200c	胰腺癌	临床前研究	[22]

治疗措施	药物名称	肿瘤类型	研究现状	参考文献/临床试验编号
单克隆抗体	TAB004	胰腺导管腺癌	临床前研究	[23]
	Gatipotuzumab	复发性卵巢上皮癌	临床Ⅱ期	[32]/NCT01899599
	PankoMab-GEX	TA-MUC1阳性癌症	临床Ⅰ期	[25]/NCT0122624
	Oregovomab	复发性卵巢癌	临床Ⅱ期	NCT05335993
ADC疗法	16A+MMAE	非小细胞肺癌	临床前研究	[33]
	SAR566658	胰腺癌、宫颈癌、膀胱癌、卵巢癌与乳腺癌	临床前研究	[28]
		恶性肿瘤	临床Ⅰ期	NCT01156870
		三阴性乳腺癌	临床Ⅱ期	NCT02984683
	3D1-MMAE	肺癌、三阴性乳腺癌	临床前研究	[34]
	BM7-PE MUC1	结直肠癌	临床Ⅱ期	NCT04550897
	M1231	实体瘤	临床Ⅰ期	NCT04695847
	DMUC5754A	卵巢癌、不可切除胰腺癌	临床Ⅰ期	[30]
CAR-T 疗法	MUC28z CAR T	三阴性乳腺癌症	临床前研究	[35]
	CAR-MUC1-IL22 T细胞	头颈部鳞状细胞癌	临床前研究	[36]
	huMNC2-CAR44 T细胞	转移性乳腺癌	临床Ⅰ期	NCT04020575
	JCAR020	实体瘤	临床Ⅰ期	NCT02498912

治疗措施	药物名称	肿瘤类型	研究现状	参考文献/临床试验编号
单克隆抗体	TAB004	胰腺导管腺癌	临床前研究	[23]
	Gatipotuzumab	复发性卵巢上皮癌	临床Ⅱ期	[32]/NCT01899599
	PankoMab-GEX	TA-MUC1阳性癌症	临床Ⅰ期	[25]/NCT0122624
	Oregovomab	复发性卵巢癌	临床Ⅱ期	NCT05335993
ADC疗法	16A+MMAE	非小细胞肺癌	临床前研究	[33]
	SAR566658	胰腺癌、宫颈癌、膀胱癌、卵巢癌与乳腺癌	临床前研究	[28]
		恶性肿瘤	临床Ⅰ期	NCT01156870
		三阴性乳腺癌	临床Ⅱ期	NCT02984683
	3D1-MMAE	肺癌、三阴性乳腺癌	临床前研究	[34]
	BM7-PE MUC1	结直肠癌	临床Ⅱ期	NCT04550897
	M1231	实体瘤	临床Ⅰ期	NCT04695847
	DMUC5754A	卵巢癌、不可切除胰腺癌	临床Ⅰ期	[30]
CAR-T 疗法	MUC28z CAR T	三阴性乳腺癌症	临床前研究	[35]
	CAR-MUC1-IL22 T细胞	头颈部鳞状细胞癌	临床前研究	[36]
	huMNC2-CAR44 T细胞	转移性乳腺癌	临床Ⅰ期	NCT04020575
	JCAR020	实体瘤	临床Ⅰ期	NCT02498912

疫苗种类	产品名称	肿瘤类型	研究现状	参考文献/临床试验编号
DNA疫苗	pVAX1-MUC1-VNTR₆DNA疫苗	胰腺癌	临床前研究	[37]
DNA疫苗	survivin/ MUC1 (MS)-IL-2-CpG	结直肠癌	临床前研究	[52]
病毒载体疫苗	TG4010	前列腺癌、肾癌	临床Ⅱ期	[53]
	TG4010	非小细胞肺癌	临床Ⅱ/Ⅲ期	[41]
	ETBX-061	前列腺癌	临床Ⅰ期	[54]
	ETBX-061	结直肠癌、胆管癌	临床Ⅰ期	[42]
树突状细胞疫苗	CVac	卵巢癌	临床Ⅱ期	[43]
树突状细胞疫苗	CVac	胰腺癌	临床Ⅱ期	NCT02310971
亚单位疫苗	L-BLP25	乳腺癌	临床Ⅱ期	[55]
		非小细胞肺癌	临床Ⅱ/Ⅲ期	[56-57]
		多发性骨髓瘤	临床Ⅱ期	[58]
		转移性结直肠癌	临床Ⅱ期	[59-60]
		前列腺癌	临床Ⅱ期	NCT01496131
	MUC1-Poly-ICLC	结直肠癌	临床Ⅰ/Ⅱ期	[61]
	ImMucin	多发性骨髓瘤	临床Ⅰ/Ⅱ期	[47]
糖肽疫苗	ONT-10	乳腺癌、卵巢癌	临床Ⅰ期	NCT02270372
	ONT-10	实体瘤	临床Ⅰ期	NCT01556789
	Theratope	转移性乳腺癌	临床Ⅲ期	[62-63]

Research Progress of Mucin in Tumor Immunotherapy

黏蛋白在肿瘤免疫治疗中的研究进展

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 4

References 66

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Yanhua LIU, Rui GUO, Yanyi LI, Jinli CHEN. Progress on the Development of Vaccines Related to Chronic Respiratory Diseases [J]. Current Biotechnology, 2025, 15(3): 396-403.
[2]	Yuqin BIAN, Keran DONG, Junzi LU, Enming ZHONG, Wanying GU, Jingshu ZHAO, Hongshu SUI. Clinical Progress in Targeted Therapy and Immunotherapy in Breast Cancer [J]. Current Biotechnology, 2025, 15(2): 234-240.
[3]	Jian QIAO, Shuai ZENG, Yang ZHANG, Gelin XU. Application of Recombinant Trypsin in Tissue Isolation of Primary Hamster Kidney Cells [J]. Current Biotechnology, 2025, 15(1): 152-157.
[4]	Weili ZHAO, Na LYU, Huiqiang LI, Yahui HE, Lulu LI, Mingli LIANG, Yanyi LI. Research Progress of Virus-like Particles Vaccine [J]. Current Biotechnology, 2024, 14(5): 776-784.
[5]	Yaping HU, Zhenghong YU. Current Status of Research on mRNA Vaccines Against Viral Infectious Diseases [J]. Current Biotechnology, 2024, 14(4): 566-575.
[6]	Yan ZENG, Hengcheng ZHU, Kang YANG. The Mechanism of DNASE1L3 in Renal Cell Carcinoma [J]. Current Biotechnology, 2024, 14(3): 486-491.
[7]	Hongyan JIAO, Guochao LI, Liang CHANG, Yanyi LI, Lili ZHAI. Overview of Norovirus Vaccine Research [J]. Current Biotechnology, 2024, 14(1): 17-25.
[8]	Na LYU, Yanyi LI, Zhuqing MA. Advances on Prevention and Treatment of Human Respiratory Syncytial Virus [J]. Current Biotechnology, 2024, 14(1): 26-34.
[9]	Yonghong ZHANG, Yanyi LI, Ronglin LIU, Na LYU, Weiting ZHANG. Application of IgY in the Field Antiviral Medical [J]. Current Biotechnology, 2024, 14(1): 35-41.
[10]	Ronglin LIU, Ning WANG, Yanyi LI, Weiting ZHANG, Chu LUO, Weibing NIU. The Application Progress of Freeze-drying Technology in Vaccine Research and Devolopment [J]. Current Biotechnology, 2024, 14(1): 72-84.
[11]	Dan YU, Yunlong MA, Fang WAN, Jianqiang WU. Advances on Research and Application of mRNA Vaccines [J]. Current Biotechnology, 2023, 13(4): 492-498.
[12]	Cancan PENG, Huiming WANG. Establishment of Anti-glomerular Basement Membrane Nephritis Model Suitable for Immunotherapy in Rats [J]. Current Biotechnology, 2022, 12(3): 473-478.
[13]	Shuxiang LI, Liping AN, Dejuan LIANG, Kaixuan WANG, Jianguo ZHAO. Research Progress on the Treatment of Prion Disease [J]. Current Biotechnology, 2022, 12(2): 229-235.
[14]	Wengui LI, Yatang CHEN. The Status Progress in the Research of Recombinant Vaccine Based on Canarypox Virus [J]. Current Biotechnology, 2022, 12(1): 36-43.
[15]	Dan LI, Haozhi SONG, Weisong GAO, Xingjian LIU, Zhifang ZHANG, Yinyu LI. Prokaryotic Expression and Immunogenicity Detection of the H Protein of Peste des Petits Ruminants Virus [J]. Current Biotechnology, 2021, 11(6): 770-776.